Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 7-25

  Jain, R K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug delivery; Gene expression and function; Intravital microscopy; Molecular imaging

Indexed keywords

LIPOSOME; MONOCLONAL ANTIBODY;

ANGIOGENESIS; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CELL ADHESION; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; IMAGING; IN VIVO STUDY; INTERSTITIUM; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 0035816177     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00306-6     Document Type: Conference Paper

References (204)

1. The nation's investment in cancer research: A budget proposal for fiscal year 1999
2. Barriers to drug delivery in solid tumors
3. Transport phenomena in tumors
4. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia
5. Geometric resistance to blood flow in solid tumors perfused ex vivo: Effects of tumor size and perfusion pressure
6. Techniques in tumor pathophysiology
7. Cellular membrane permeability of anthracyclines does not effect their delivery in a tissue isolated tumor
8. Tissue-isolated human tumor xenografts in athymic nude mice
9. Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer
10. Cells shed from tumors show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity
11. Geometric resistance to blood flow and vascular network architecture in human colorectal carcinoma
12. Microcirculatory flow changes during tissue growth
13. Dynamics of neovascularization in normal tissue
14. Angiogenesis and growth of isografted bone: Quantitative in vivo assay in nude mice
15. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice
16. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows
17. Rolling in P-selectin deficient mice is reduced but not eliminated in the dorsal skin
18. Mice lacking E-selectin show normal rolling but reduced arrest of leukocytes on cytokine-activated microvascular endothelium
19. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
20. Tumor induction of VEGF promoter activity in stromal cells
21. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis
22. VEGF modulation by targeting HIF-1aæHREæ VEGF cascade differentially regulates vascular response and growth rate in tumors
23. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
24. Transparent window models and intravital microscopy: Imaging gene expression, physiological function and drug delivery in tumors
25. Quantitation and physiological characterization of bFGF and VEGF/VPF induced vessels in mice: Effect of microenvironment on angiogenesis
26. Tumor-host interactions in the gall bladder suppress distal angiogenesis and tumor growth: Role of TGFb
27. Quantitative angiogenesis assays: Progress and problems
28. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: An intravital microscopic study in mice
29. Predominant role of endothelial nitric oxide synthase in VEGF-induced angiogenesis and vascular permeability
30. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: Potential role of host-tumor interaction
31. Perfusion of single tumor microvessels: Application to vascular permeability measurement
32. Effect of anti-VEGF antibody on tumor microvessel permeability: Local versus systemic treatment
33. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma
34. Flow velocity in the superficial lymphatic network of the mouse tail
35. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
36. Return of lymphatic function following flap transfer for acute lymphedema
37. Mechanics of interstitial-lymphatic transport: Theoretical foundation and experimental validation
38. Transport in lymphatic capillaries: II. Microscopic velocity measurement with fluorescence recovery after photobleaching
39. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory
40. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation
41. Imaging of activated natural killer cells in mice by positron emission tomography: Preferential uptake in tumors
42. Analysis of cell flux in the parallel plate flow chamber: Implications for cell capture studies
43. Erythrocytes enhance lymphocyte rolling and arrest in vivo
44. A lateral view flow system for studies of cell adhesion and deformation under flow conditions
45. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution
46. Effect of glucose and galactose on red blood cell membrane deformability
47. Solid stress inhibits the growth of multicellular tumor spheroids
48. Kinetics of adhesion molecule expression and spatial organization using targeted sampling fluorimetry
49. In vitro and in vivo quantification of adhesion between leukocytes and vascular endothelium
50. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
51. Transport of fluid and macromolecules in tumors, II. Role of heterogeneous perfusion and lymphatics
52. Transport of fluid and macromolecules in tumors, III. Role of binding and metabolism
53. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution
54. Biodistribution of monoclonal antibodies: Scale-up from mouse to man using a physiologically based pharmacokinetic model
55. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice
56. Residence time distributions of various tracers in tumors: Implications for drug delivery and blood flow measurement
57. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
58. Dynamics of drug transport in solid tumors: Distributed parameter model
59. Pharmacokinetics of methotrexate in solid tumors
60. Effect of transvascular fluid exchange on arterio-venous pressure relationship: Implication for temporal and spatial heterogeneities in tumor blood flow
61. Time dependent behavior of interstitial pressure in solid tumors: Implications for drug delivery
62. Analysis of macro and microscopic fluid transport mechanisms in living tissues
63. Extracellular water measurements: Organ tracer kinetics of bromide and sucrose in rats and man
64. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies
65. Local imbalance of angiogenic and anti-angiogenic regulators: A potential mechanism of focal necrosis and dormancy in primary tumors
66. Tumor angiogenesis
67. Determinants of tumor blood flow: A review
68. Angiogenesis in cancer and other diseases
69. Role of tumor vascular architecture in nutrient and drug delivery: An invasion percolation model
70. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors
71. Fractals and cancer
72. Scale-invariant behavior and vascular network formation in normal and tumor tissue
73. Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions
74. Intussusceptive microvascular growth in solid tumors: A novel mechanism of tumor angiogenesis
75. Fractal characteristics of tumor vascular architecture: Significance and implications
76. Cancer, angiogenesis and fractals
77. Tumor blood flow: Characterization, modifications and role in hyperthermia
78. Viscous resistance to blood flow in solid tumors: Effect of hematocrit on intratumor blood viscosity
79. Effect of red blood cell rigidity on tumor blood flow: Increase in viscous resistance during hyperglycemia
80. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial pressure in tumors
81. Tissue perfusion inhomogeneity during early tumor growth in rats
82. 2H-nuclear magnetic resonance imaging of tumor blood flow: Spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma
83. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution
84. Understanding barriers to drug delivery: High resolution in vivo imaging is key
85. Fluorescence ratio imaging and optical sectioning: Effect of glucose on spatial and temporal gradients
86. O2 gradients in solid tumors in vivo: Simultaneous high-resolution measurements reveal a lack of correlation
87. Fluorescence ratio imaging measurement of pH gradients: Calibration and application in normal and tumor tissues
88. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy
89. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice
90. Acid production in glycolysis-deficient and parental tumors in vivo
91. Continuous noninvasive monitoring of pH and temperature in rat Walker 256 carcinoma during normoglycemia and hyperglycemia
92. Oxygenation in tumors by modified hemoglobins
93. Response of tumours to hyperglycaemia: Characterization, significance and role in hyperthermia
94. 31P NMR
95. Formation of endothelial cell networks
96. Transport of molecules across tumor vasculature
97. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
98. Microvascular permeability of normal and neoplastic tissues
99. Measurement of capillary filtration coefficient in a solid tumor
100. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice
101. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
102. Water channel (Aquaporin 1) expression and distribution in mammary carcinoma and glioblastomas
103. Vascular permeability in a human tumor xenograft: Molecular size-dependence and cut-off size
104. Vascular permeability in a human tumor xenograft: Molecular charge dependence
105. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
106. Openings between defective endothelial cells contribute to tumor vessel leakiness
107. Neovasculature induced by vascular endothelial growth factor is fenestrated
108. Endothelial cell death, angiogenesis, and microvascular function following castration in an androgen-dependent tumor: Role of VEGF
109. Leaky vessels? Call Ang1!
110. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor and placenta growth factor
111. Time-dependent changes in vascular permeability and morphology in established human tumor xenografts induced by an anti-VEGF/VPF antibody
112. Interstitial hypertension in human brain tumors: Possible role in peritumoral edema formulation
113. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy
114. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse
115. O2 in tumors
116. Interstitial hypertension in superficial metastatic melanomas in humans
117. Interstitial fluid pressure in intracranial tumors in patients and in rodents: Effect of anti-edema therapy
118. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment
119. Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size
120. Transport of molecules in the tumor interstitium: A review
121. Interstitial hypertension in human breast and colorectal tumors
122. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma
123. Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response
124. Oncotic pressure in solid tumor is elevated
125. Tumor angiogenesis and interstitial hypertension
126. Fluid and protein fluxes across small and large pores in the microvasculature: Applications of two-pore equations
127. Fluorescence photobleaching with spatial Fourier analysis: Measurement of diffusion in light-scattering media
128. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching
129. Diffusion and partitioning of proteins in charged agarose gels
130. Hindered diffusion in agarose gels: Test of effective medium mode
131. Lateral diffusion of small compounds in human stratum corneum and model lipid bilayer systems
132. Extravascular diffusion in normal and neoplastic tissues
133. Diffusion and convection in normal and neoplastic tissues
134. Diffusion of macromolecules in agarose gels: Comparison of linear and globular configurations
135. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors
136. Direct in vivo measurement of targeted binding in a human tumor xenograft
137. Intratumoral infusion of fluid: Estimation of hydraulic conductivity and compliance and implications for the delivery of therapeutic agents
138. Role of extracellular matrix assembly in interstitial transport in solid tumors
139. Micropharmacology of monoclonal antibodies in solid tumor: Direct experimental evidence for a binding site barrier
140. Quantification of transport and binding parameters using fluorescence recovery after photobleaching: Potential for in vivo applications
141. Measurement of mass transport and reaction parameters in bulk solution using photobleaching: Reaction limited binding regime
142. Effect of bivalent interaction upon apparent antibody affinity: Experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays
143. In vitro measurement and screening of monoclonal antibody affinity using fluorescence photobleaching
144. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies
145. Selectin and integrin mediated T lymphocyte rolling and arrest on TNFα-activated endothelium is augmented by erythrocytes
146. Role of erythrocytes in leukocyte-endothelial interactions: Mathematical model and experimental validation
147. TNFα-induced leukocyte-adhesion in normal and tumor vessels: Effect of tumor type, transplantation site and host
148. Leukocyte-rolling increases with age
149. A method for labeling cells for positron emission tomography (PET) studies
150. Kinetics of interleukin-2 induced changes in rigidity of human natural killer cells
151. Leukocyte-endothelial adhesion and angiogenesis in tumors
152. Reduction of rigidity in human activated natural killer cells by thioglycollate treatment
153. Modulation of A-NK cell rigidity: In vitro characterization and in vivo implications for cell delivery
154. Localization of activated natural killer cells in MCaIV mammary carcinoma grown in cranial windows in C3H mice
155. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation
156. Interleukin-2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: Implications for vascular leak syndrome
157. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium
158. Suppression of tumor growth in vivo by local and systemic 90 K level increase
159. Adhesion of activated natural killer cells to TNF-α treated endothelium under physiological flow conditions
160. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β
161. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β
162. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells
163. Modulation of the organ microenvironment for treatment of cancer metastasis
164. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: Role of VEGF-receptor 2 and host VEGF-A
165. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte
166. Effects of basic fibroblast growth factor on human microvessel endothelial cell migration on collagen I correlates with adhesion and is cell density dependent
167. Animal scale-up
168. Physiologically based pharmacokinetic modeling: Principles and applications
169. Physiologically based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy
170. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies: Evaluation using a physiologically-based pharmacokinetic model
171. Tumor pretargeting for radioimmunodetection and radioimmunotherapy: Evaluation using a physiologically-based pharmacokinetic model
172. Effect of inhomogeneities and finite boundaries on temperature distribution in a perfused medium with application to tumors
173. Transient temperature distributions in an infinite perfused medium due to a time-dependent, spherical heat source
174. Differential response of normal and tumor microcirculation to hyperthermia
175. Role of nitric oxide in tumor microcirculation: Blood flow, vascular permeability, and leukocyte-endothelial interactions
176. Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues
177. Reduction of interstitial fluid pressure after TNF-α treatment of human melanoma xenografts
178. Effect of tumor necrosis factor-α on vascular resistance, nitric oxide production, glucose and oxygen consumption in perfused, tissue-isolated human melanoma xenografts
179. Role of nitric oxide in angiogenesis and microcirculation in tumors
180. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: Comparison with experimental data
181. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data
182. Effect of radiation on interstitial fluid pressure and oxygenation in a human colon carcinoma xenograft
183. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft
184. Nicotinamide can lower tumor interstitial fluid pressure: Mechanistic and therapeutic implications
185. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline
186. Effect of hemodilution and resuscitation on tumor interstitial fluid pressure, blood flow, and oxygenation
187. Interstitial fluid pressure in solid tumors following hyperthermia: Possible correlation with therapeutic response
188. Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster
189. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions
190. VEGF receptor-2 blocking antibody potentiates radiation-induced long term control of human tumor xenografts
191. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: Network analysis and mechanistic interpretation
192. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure
193. Enhancement of fluid filtration across tumor vessels: Implications for delivery of macromolecules
194. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy
195. Delivery of molecular medicine to solid tumors
196. 1996 Landis award lecture: Delivery of molecular and cellular medicine to solid tumors
197. The next frontier of molecular medicine: Delivery of therapeutics